Efficacy and safety of dabigatran in prevention of venous thromboembolism in patients undergoing major orthopedic surgeries: a review

Varsha Narayanan*, Amit Bhargava

ABSTRACT
Thromboprophylaxis with anticoagulants can significantly reduce the risk of patients developing symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE) and VTE related mortality post major orthopedic surgeries like total hip and knee replacement surgeries. Dabigatran, a directly acting oral anticoagulant (DOAC) and direct thrombin inhibitor, is an available option for VTE prophylaxis having comparable efficacy to low molecular weight heparins (LMWH), other DOACs and Warfarin, once daily dosing, and comparable safety and bleeding risk to both LMWH and Aspirin. Dabigatran is currently the only DOAC with an available and marketed reversing agent. A review of Dabigatran’s clinical efficacy and safety is presented here. Therefore, Dabigatran represents a balanced thromboprophylaxis option for VTE prevention in patients undergoing major orthopedic surgeries.

Keywords: Dabigatran, Thrombin, Direct oral anticoagulants, Total hip and knee replacement, THR, Anticoagulants, Venous thromboembolism, Deep vein thrombosis, Pulmonary embolism

INTRODUCTION
Orthopedic surgeries are high risk factors for developing postoperative DVT and VTE.

In absence of thromboprophylaxis, confirmed DVT post lower limb orthopedic surgery is 40–60% with 10-14% progressing to symptomatic VTE, and around 5% showing PE, all usually seen post discharge from hospital. One third are proximal DVTs seen more with hip surgeries with greater risk to embolize. The cumulative risk of venous thromboembolism lasted for up to three months (median 21-34 days) and one month (median 12-20 days) after hip and knee surgery respectively. Increased VTE risk post orthopedic surgeries can be due to immobilization, prolonged bed rest leading to venous stasis, surgical manipulations causing endothelial trauma and hyper-coagulable state, with presence of medical comorbidities increasing risk further.

Contrary to perception, autopsy studies indicate similar incidence of PE in Asian and Western countries. A multicentric study for the evaluation of patients at risk for venous thromboembolism in the acute hospital care setting (ENDORSE- cross-sectional survey in Asian countries: India, Thailand, Pakistan, and Bangladesh), reported similar VTE risk in surgical patients ranging from 44% to 62%, which was similar to the proportion, reported for all countries studied (overall: 64%; range: 44%-80%).

Lupin Medical Services and Research, BKC, Mumbai, Maharashtra, India

Received: 28 November 2018
Revised: 13 December 2018
Accepted: 14 December 2018

*Correspondence:
Dr. Varsha Narayanan,
E-mail: drvarsha@rediffmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: http://dx.doi.org/10.18203/issn.2455-4510.IntJResOrthop20185147
With routine VTE prophylaxis in orthopaedic patients, fatal PE is uncommon, and the rates of symptomatic VTE within three months can be reduced to as low as 1-2%. Pharmacoprophylaxis options for VTE prevention recommended include low molecular weight heparins (LMWH) LMWH, fondaparinux, direct (or newer/non-vitamin K) oral anticoagulants (DOACs/NOACs - dabigatran, apixaban, rivaroxaban), low dose unfractionated heparin (LDUH), adjusted-dose vitamin K antagonist (Warfarin), and aspirin (AAOS 20116 and ACCP 2012).7

Aspirin is not recommended to be used alone or as the only thromboprophylaxis agent in any patient group as other agents (LMWH, DOACs and warfarin) are more effective for prevention of VTE (ACCP 2008. SIGN 2010 updated 2015).8,9 LMWH are conventionally first line anticoagulants in hospitalized patients, however being injectable, they do not represent a compliant option for patients once discharged from hospital. Warfarin has a slow onset and offset and is known to be associated especially in Asian populations with increased risk of intracranial hemorrhage (ICH), requires meticulous INR monitoring, and has associated high food-drug interactions.5,10

ACCP recommends that in patients undergoing major orthopaedic surgery who decline or are uncooperative with injections or a mechanical device like IPCD, the DOACs dabigatran or apixaban and if unavailable, rivaroxaban or adjusted-dose VKA should be used rather than alternative forms of prophylaxis.7

DOACs currently represent the most appropriate and balanced option for VTE risk reduction in patients discharged from hospital.

**ORAL DIRECT THROMBIN INHIBITOR: DABIGATRAN**

Dabigatran is an oral direct thrombin inhibitor approved for VTE prophylaxis in orthopedic surgeries. Thrombin (IIa) is the key and central factor in the coagulation pathway. Table 1 shows mechanism of action of dabigatran as well as the dosing and treatment duration of dabigatran. Dabigatran acts on both free as well as fibrin bound thrombin as it has a different active binding site from the exosites used by fibrin and antithrombin, while LMWH act only on free thrombin.14

---

**Table 1: Dabigatran action and dosing.**

| Dabigatran: mechanism of action11-13 | Dose16 | Duration |
|------------------------------------|--------|----------|
| Inhibits the following actions of thrombin | VTE prophylaxis for Orthopedic surgeries: | |
| • Conversion of fibrinogen to fibrin | • Once daily dose of 220 mg (2 capsules of 110mg). | TKR: 10-14 days |
| • Activation of Factor XIII which cross links fibrin | • Initiation, if within 1-4 hours of surgery is recommended with 1 capsule. | THR: 28-35 days |
| • Feedback activation of factor V, VII and XI | • It can be taken irrespective of food and the capsule is to be swallowed intact. | |
| • Binding to thrombomodulin to activate protein C | | |
| • Activation of platelet aggregation | | |
| • Fibroblast proliferation18 | | |

Onset of Dabigatran action occurs in half to 1 hour with a half-life of 12-14 hours. It does not show CYP dependent metabolism and drug interactions so can be given even in moderate hepatic impairment, however interacts with Pgp inhibitors and due to majority renal clearance, should not be given if creatinine clearance falls below 30ml/min (<50 ml/min if concomitant Pgp inhibiting drugs are being co-administered). Dabigatran is contraindicated in patients with active pathological bleeding, mechanical or prosthetic valves and history of hypersensitivity to Dabigatran and does not have controlled studies in pregnancy or lactation to recommend its use.15,16

**CLINICAL EFFICACY AND SAFETY OF DABIGATRAN**

Three phase III studies compare Dabigatran to standard dose of Enoxaparin 40mg SC OD to assess VTE rate and bleeding risk in patients undergoing Hip and Knee replacement surgery (Table 2). Patients were treated for 6-10 days post TKR and 28-35 days post THR with a 3 month follow up period in all 3 studies. The REMODEL (TKR) and RENOVATE (THR) studies showed comparable efficacy and safety in VTE prevention and bleeding risk of Dabigatran doses to standard 40mg SC Enoxaparin.17,18 In RENOVATE II, though the total VTE incidence as well as bleeds (major and clinically relevant non major - CRNM bleeds) were comparable to Enoxaparin 40mg OD, the rate of proximal DVT, major VTE and VTE related mortality was significantly lower than Enoxaparin (2.1vs 3.9%; P=0.04 and 2.2 vs 4.2%; P=0.03 respectively).19 This reduced risk of major VTE and VTE-related mortality was also seen in the Indian population sub-analyzed in RENOVATE II : 179 Indian patients (91 Dabigatran; 88 Enoxaparin : 7.9% vs 9.9%). This showed that in the normal clinical setting, Dabigatran was an effective and well tolerated option to LMWH in patients who had undergone THR and TKR and may offer greater convenience in the outpatient post discharged patients.20
| Study                | Total VTE | Symptomatic DVT | Symptomatic PE | Major VTE+ all cause mortality | Major bleed | CRNM bleed |
|---------------------|-----------|-----------------|----------------|---------------------------------|-------------|------------|
|                     | Dabi      | Enoxa           | Dabi           | Enoxa                           | Dabi        | Enoxa      | Dabi      | Enoxa   | Dabi      | Enoxa   |
| **REMODEL**<sup>17</sup> (2007) N=2086 TKR | 40.5 (150mg) | 36.4 (220mg) | 0.4 (150mg) | 0.1 (220mg) | 1.2 | 0.1 (150mg) | 0 (220mg) | 0.1 | 3.8 (150mg) | 2.6 (220mg) | 3.5 | 1.3 (150mg) | 1.5 (220mg) | 1.3 | 6.8 (150mg) | 5.9 (220mg) | 5.3 |
| **RENOVATE**<sup>18</sup> I<sup>18</sup> (2007) N=3463 THR | 8.6 (150mg) | 6.0 (220mg) | 0.8 (150mg) | 0.5 (220mg) | 0.1 | 0.1 (150mg) | 0.4 (220mg) | 0.3 | 4.3 (150mg) | 3.1 (220mg) | 3.9 | 1.3 (150mg) | 2.0 (220mg) | 1.6 | 4.7 (150mg) | 4.2 (220mg) | 3.5 |
| **RENOVATE**<sup>19</sup> II<sup>19</sup> (2011) N=2055; THR | 7.7 (220mg) | 8.8 | 0 (220mg) | 0.4 | 0.1 (220mg) | 0.2 | 2.2* (220mg) | 4.2 | 1.4 (220mg) | 0.9 | 2.3 (220mg) | 2 |
Dabigatran and Warfarin have been compared in two studies (RECOVER and RECOVER II) to assess risk of VTE recurrence and bleeding risk in patients being treated for acute VTE. In both studies, Dabigatran was found to have similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin in 2 studies (RECOVER I,II: VTE Rate and deaths during 6 months of treatment: 2.4% vs 2.2% while major or CRNM bleeding rate: 5.3% vs 8.5%; total bleeding rate: 16.1% vs 22.2% for Dabigatran vs Warfarin with more than twice as many ICH cases in Warfarin group). 

Various metanalysis have also been published for DOACs. Comparable efficacy is seen among DOACs in treatment and prevention of recurrence of VTE however Dabigatran was associated with a significantly lower risk of ‘major or CRNM bleed’ compared with rivaroxaban and apixaban, and when compared with Enoxaparin, the relative risk of clinically relevant bleeding was higher with rivaroxaban (OR 1.25), and similar with Dabigatran (OR 1.12).

When comparing apixaban, aspirin, Dabigatran, rivaroxaban, warfarin and placebo, the risk of the composite efficacy outcome (VTE and VTE-related death) seen on metanalysis was significantly lower with the DOACs and warfarin INR 2.0–3.0 compared with aspirin, with Dabigatran and apixaban being associated with comparable rate of major and CRNM bleeds to Aspirin and significantly lower than Warfarin, while rivaroxaban having higher and comparable rate of major and CRNM bleeds to Aspirin and Warfarin respectively.

The efficacy and safety of DOACs in the geriatric population (10 RCTs included 25,031 elderly participants >75 years) showed that DOACs did not cause excess bleeding (9.3% vs 8.7%; OR = 1.07 for major/CRNM bleeds of Dabigatran versus conventional therapy; vitamin K antagonists, LMWH, aspirin, placebo) and were associated with equal or greater efficacy than conventional therapy. Overall DOACs resulted in a significantly lower risk of VTE or VTE-related death than conventional therapy (3.7% vs 7.0%; OR 0.45) in geriatric age group.

Dabigatran is the only DOAC to have a reversible agent currently available in the market: Idarucizumab. Idarucizumab in studies showed a median maximum 100% percentage reversal of Dabigatran (assessed by diluted thrombin time/ecarin clotting time) with a median time to the cessation of bleeding of 2.5 hours and a median time to surgery of 1.6 hours with 93% normal hemostasis.

**CONCLUSION**

The DOACs or NOACs (Newer Oral Anticoagulants) represent a more balanced, compliant, and effective approach for VTE preventions in patients undergoing lower limb orthopedic surgery especially for patients discharged from hospital. Dabigatran in comparison to Enoxaparin (LMWH) has shown comparable efficacy with better risk reduction of proximal DVT, major VTE and VTE related mortality with the added advantage of oral dosing. Dabigatran efficacy is comparable to Warfarin as well as the other NOACs, and significantly better efficacy than Aspirin, in VTE prevention. Safety and bleeding risk of Dabigatran is similar to both LMWH and aspirin and lower than warfarin. Dabigatran has an effective available reversible agent. Therefore, Dabigatran can be a practical option for orthopedic surgeons for VTE prevention in patients undergoing lower limb orthopedic surgeries like TKR and THR.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not required

**REFERENCES**

1. Kakkar KA, Rushton-Smith S.K. Incidence of Venous Thromboembolism in Orthopedic Surgery. Thromboembolism Orthopedic Surg. 2013. DOI 10.1007/978-1-4471-4336-9_2
2. Caprini JA. Update on Risk Factors for Venous Thromboembolism. CME series jointly sponsored by the Elsevier Office of Continuing Medical Education (EOCME) and Excerpta Medica, Inc. Am J Med. 2005.
3. Flevas DA, Megaloikonomos PD, Dimopoulous L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thrombosis J 2008;3:136–48.
4. Wang KL, Yap ES, Gotto S, Zhang S, Siu CW, Chiang CE. The diagnosis and treatment of venous thromboembolism in Asian patients. Thrombosis J 2018;16:4.
5. Cohen AT, Tapson VF, Bergmann JJ, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387–94.
6. Mont MA, Jacobs JJ. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011;19(12):777-8.
7. Ytter YF. Prevention of VTE in Orthopedic Surgery Patients Antithrombotic Therapy and prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012;141(2):278–325.
8. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:381-453.
9. Scottish Intercollegiate Guidelines Network (SIGN). Prevention and management of venous thromboembolism. SIGN publication no. 122. Edinburgh: SIGN; 2010. 2015.
10. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary Supplements. Expert Opin Drug Saf. 2006;5(3):433-51.
11. Narayanan S. Multifunctional role of thrombin. Ann Clin Lab Sci. 1999;29(4):275-80.
12. Lee C J, Ansell JE. Direct Thrombin Inhibitors. Br J Clin Pharmacol. 2011;72(4):581–92.
13. Bogatkevich GS, Bradley AL, Silver RM. Dabigatran, a direct thrombin inhibitor, blocks differentiation of normal fibroblasts to a myofibroblast phenotype and demonstrates anti-fibrotic effects on scleroderma lung fibroblasts. Arthritis Rheum. 2009;60(11):3455–64.
14. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant. J Med Toxicol. 2011;7:281–7.
15. Shulman S, Majeed A. A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery. Drug Saf. 2011;34 (6):449-63.
16. PRADAXA: USFDA Full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/labelf/2015/022512s028lbl.pdf. Accessed on 3 June 2018.
17. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP et al. Oral Dabigatran etexilate vs. subcutaneous Enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-85.
18. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus Enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–56.
19. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al. Oral Dabigatran versus Enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*), a double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721–9.
20. Malhotra R, Babhulkar S, Sanjib KB, Clemens A, Dadi A, Iyer R, Kamath S et al. Thromboprophylaxis with Dabigatran after total hip arthroplasty in Indian patients: A subanalysus of a double-blind, double dummy, randomized RE-NOVATE II study. Asian J Surg. 2017;40:145-51.
21. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of Acute Venous Thromboembolism with Dabigatran or Warfarin and Pooled Analysis. Circulation. 2014;129:764-72.
22. Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One. 2015;10(12):e0144856.
23. Outes AG, Terleira-Fernandez AI, Suarez-Gia ML, Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus Enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675.
24. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New Oral Anticoagulants in Elderly Adults: Evidence from a Meta-Analysis of Randomized Trials. Am Geriatr Soc. 2014.
25. Pollack CV Jr, Reilly PA, Ryn JV, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377:431-41.

Cite this article as: Narayanan V, Bhargava A. Efficacy and safety of dabigatran in prevention of venous thromboembolism in patients undergoing major orthopedic surgeries: a review. Int J Res Orthop 2019;5:196-200.